|
|
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pharmacogenetics Section, Laboratory of Reproductive and Developmental Toxicology, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina
Received for publication February 5, 2007.
Accepted for publication February 21, 2007.
| Abstract |
|---|
|
|
|---|
Mouse hepatocytes retain CAR in the cytoplasm, thus making the nuclear translocation an initial step of its activation by drugs. CAR forms a complex with Hsp90 and cochaperone CCRP (cytoplasmic CAR retention protein) in the cytoplasm. In response to PB, the complex recruits protein phosphatase 2A before translocation of CAR into the nucleus. The protein phosphatase inhibitor okadaic acid represses PB-induced nuclear translocation of CAR in mouse primary hepatocytes (Kawamoto et al., 1999
). PB triggers the nuclear translocation without directly binding to the receptor (Swales and Negishi, 2004
). These facts indicate that cellular signals are involved in regulating the cytoplasmic retention and nuclear translocation of CAR. Two observations providing insight into such a signal have been reported: the attenuation by epidermal growth factor (EGF) of CAR-mediated trans-activation of PBREM by PB and the augmentation by the MEK inhibitor U0126 of PB induction of the CYP2B gene in rat primary hepatocytes (Bauer et al., 2004
; Joannard et al., 2006
). MEK is a downstream protein kinase of EGF signaling and activates extracellular signal-regulated kinase (ERK). Here we have investigated the MEK-ERK signal for its ability to regulate the intracellular localization of CAR in mouse primary hepatocytes. The experimental results presented here suggest that the activation of ERK is the signal that retains CAR in the cytoplasm.
| Materials and Methods |
|---|
|
|
|---|
|
RNA Preparation and RT-PCR. Total RNAs were extracted from hepatocytes treated with PB (1 mM), TCPOBOP (250 nM), EGF (10 µg/ml), HGF (10 µg/ml), U0126 (2.5 or 25 µM), or U0124 (25 µM) for 8 h, using TRIzol reagent (Invitrogen, Carlsbad, CA). cDNAs were synthesized using SuperScript II reverse transcriptase (Invitrogen), and real-time PCR was performed using the ABI Prism 7700 (Applied Biosystems, Foster City, CA). The CYP2B10 cDNA was amplified using 5'-AAAGTCCCGTGGCAACTTCC-3' and 5'-TCCCAGGTGCACTGTGAACA-3' for 5'- and 3'-primers, respectively. Amplified cDNA was measured using 6-carboxyfluorescein-ACCCCGTCCCCTGCCCCTCTT5-carboxytetramethylrhodamine as a CYP2B10 probe. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA was amplified as an internal control using the TaqMan rodent GAPDH control reagents (Applied Biosystems). The levels of a given mRNA were normalized to the GAPDH mRNA level.
Luciferease Reporter Assays. HepG2 cells were cultured in minimal essential medium supplemented with 10% fetal bovine serum. Mouse CAR (mCAR) expression plasmids (0.1 µg) were cotransfected with PBREM-pGL3 (0.1 µg) and phRL-tk (0.1 µg) into HepG2 cells using FuGENE6 transfection reagent (Roche, Indianapolis, IN). Mouse primary hepatocytes were cotransfected with 1.8 kb-CYP2B6 promoter-pGL3 (10 µg) and phRL-tk (5 µg) using electroporation. After being treated with DMSO or a given chemical at the concentrations indicated, the cells were lysed and subjected to luciferase assays using the dual-luciferase reporter assay system (Promega, Madison, WI).
Western Blot. The nuclear extracts and cytosolic fractions were prepared from these hepatocytes using methods established previously (Dignam et al., 1983
). Nuclear and cytosolic proteins were resolved on a SDS-10% polyacrylamide gel and transferred to polyvinylidene difluoride membrane using Hoefer SemiPhior (GE Healthcare, Chalfont St. Giles, Buckinghamshire, UK) with Nu-PAGE transfer buffer (Invitrogen). See Blue Plus2 PreStained Standard (Invitrogen) was used as molecular weight markers. Western blot analysis was performed by using anti-rabbit IgG, anti-ERK1/2, anti-phospho-ERK1/2, or anti-CAR polyclonal antibody (Kobayashi et al., 2003
). Protein bands were visualized using ECL Plus Western blotting detection reagent (GE Healthcare).
| Results and Discussion |
|---|
|
|
|---|
|
ERK-Mediated Repression of CAR Translocation. CAR is retained in the cytoplasm of unexposed mouse primary hepatocytes and translocates into the nucleus in response to CAR activators such as PB and TCPOBOP, thus making the nuclear translocation the initial step of CAR activation (Kawamoto et al., 1999
). Because CAR is spontaneously accumulated in the nucleus of HepG2 cells (Kawamoto et al., 1999
) in which U0126 did not alter the CAR-mediated transcription, we examined the possibility that U0126 might inhibit the nuclear translocation of CAR in the mouse primary hepatocytes. To this end, mouse primary hepatocytes were treated with U0126 and/or TCPOBOP, from which the cytosols and nuclear extracts were prepared. Western blot analyses of the nuclear extracts showed the accumulation of CAR after the treatment with U0126 in the manner associated with the dephosphorylation of ERK1/2, whereas the nuclear CAR accumulation by TCPOBOP was independent of the function of ERK1/2 (Fig. 3). Treatment with the inactive inhibitor U0124 caused neither accumulation of CAR in the nucleus nor dephosphorylation of the ERK1/2. Thus, the ERK dephosphorylation by U0126 was sufficient to translocate CAR into the nucleus, activating the CAR-mediated transcription and inducing the Cyp2b10 gene in the absence of CAR activators. Consistent with the repressive role of ERK, HGF increased phosphorylation of ERK, thereby repressing CAR nuclear accumulation of in the mouse primary hepatocytes (Fig. 3B).
|
|
In addition to MEK-ERK, AMP-activated protein kinase (AMPK) has recently been suggested to activate CAR to induce the CYP2B genes by PB in the human and mouse primary hepatocytes (Rencurel et al., 2005
, 2006
; Shindo et al., 2007
). However, the process by which AMPK activates CAR is not clear at the present time. One study, using AMPK KO (
1/
2 LS/) mice, demonstrated that although AMPK does not regulate the PB-induced nuclear translocation of CAR, it may be involved in the activation of CAR in the nucleus (Rencurel et al., 2006
). Another study demonstrated that the activation of AMPK resulted in the nuclear accumulation of CAR but was not sufficient to activate CAR-mediated transcription (Shindo et al., 2007
). PB did not induce the Cyp2b10 gene in the AMPK KO mice, providing the basis of support for the notion that AMPK mediates PB induction. However, PB could not induce the Cyp2b10 gene apparently because the expression levels of the Cyp2b10 gene in the livers of nontreated AMPK KO mice were already elevated to levels near those observed in the PB-treated wild-type mice (Rencurel et al., 2006
). Although AMPK is the activating signal for PB induction, MEK-ERK seems to be the repressive signal in our study. Nevertheless, whether AMPK and ERK cross-talk to generate a cellular signal for CAR activation is an intriguing question. We used the inhibitor LY294002 and found that phosphatidylinositol 3-kinase does not regulate the nuclear translocation of CAR in mouse primary hepatocytes (data not shown). PKA has also been proposed as a possible signal molecule repressing PB induction in rat primary hepatocytes (Sidhu and Omiecinski, 1995
), but its molecular mechanism is poorly understood. Recent reports have suggested that the activation of protein kinases A and C modulated the pregnane X receptor-mediated induction of Cyp3a gene in mouse primary hepatocytes by altering the receptor interactions with coregulators (Ding and Staudinger, 2004a
,b
). Exciting research remains for the future in the signal-regulated mechanism of activation of the xenobiotic receptors CAR and pregnane X receptor.
CAR forms a complex with Hsp90 and cochaperone CCRP in the cytoplasm (Kobayashi et al., 2003
). In response to PB, the complex recruits protein phosphatase 2A before translocating CAR into the nucleus, making PB-induced CAR nuclear translocation sensitive to okadaic acid, a protein phosphatase inhibitor in mouse primary hepatocytes (Kawamoto et al., 1999
; Yoshinari et al., 2003
). Dephosphorylation of serine 202 of mouse CAR was found to be a prerequisite for the nuclear translocation occurred (Hosseinpour et al., 2005
). If ERK directly targets CAR, serine 202 can be a possible candidate of ERK phosphorylation, although the target of ERK can be the other components of the cytoplasmic CAR complex, such as CCRP and Hsp90. Identifying the phosphorylation site(s) will help us to decipher the molecular basis for the signal-regulated mechanism of CAR activation and is now the major objective of our research.
| Footnotes |
|---|
Article, publication date, and citation information can be found at http://molpharm.aspetjournals.org.
ABBREVIATIONS: CAR, constitutive active/androstane receptor; PB, phenobarbital; Hsp90, 90-kDa heat shock protein; CCRP, cytoplasmic CAR retention protein; EGF, epidermal growth factor; PBREM, phenobarbital-responsive enhancer module; MEK, mitogen-activated protein kinase kinase; U0124, 1,4-diamino-2,3-dicyano-1,4-bis(aminophenylthio)butadiene; U0126, 1,4-diamino-2,3-dicyano-1,4-bis(methylthio)butadiene; ERK, extracellular signal-regulated kinase; TCPOBOP, 1, 4-bis[2-(3,5-dichloropyridyloxy)]benzene; kb, kilobase pair(s); RT-PCR, reverse transcription-polymerase chain reaction; HGF, hepatocytes growth factor; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; mCAR, mouse CAR; DMSO, dimethyl sulfoxide; KN-62, 1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-L-tyrosyl]-4-phenylpiperazine; AMPK, AMP kinase; KO, knockout; LY294002, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one.
Address correspondence to: Dr. Masahiko Negishi, Pharmacogenetics Section, Laboratory of Reproductive and Developmental Toxicology, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina 27709. E-mail: negishi{at}niehs.nih.gov
| References |
|---|
|
|
|---|
Cobb MH, Boulton TG, and Robbins DJ (1991) Extracellular signal-regulated kinases: ERKs in progress. Cell Regul 2: 965978.[Medline]
DeSilva DR, Jones EA, Favata MF, Jaffee BD, Magolda RL, Trzaskos JM, and Scerle PA (1998) Inhibition of Mitogen-activated protein kinase kinase blocks T cell proliferation but does not induce or prevent anergy. J Immunol 160: 41754181.
Ding X and Staudinger JL (2004a) Induction of drug metabolism by forskolin: the role of the pregnane X receptor and the protein kinase A signal transduction pathway. J Phamacol Exp Ther 312: 849856.[CrossRef][Medline]
Ding X and Staudinger JL (2004b) Repression of PXR-mediated induction of hepatic Cyp3A gene expression by protein kinase C. Biochem Pharmacol 69: 867873.
Dignam JD, Lebovitz RM, and Roeder RG (1983) Accurate transcription by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 11: 14751489.
Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, Van Dyk DE, Pitts WJ, Earl RA, Hobbs F, et al. (1998) Identification of a novel inhibitor of Mitogen-activated protein kinase kinase. J Biol Chem 273: 1862318632.
Honkakoski P, Moore R, Gynther J, and Negishi M (1996) Characterization of phenobarbital-inducible mouse Cyp2b10 gene transcription in primary hepatocytes. J Biol Chem 271: 97469753.
Honkakoski P and Negishi M (1998a) Regulatory DNA elements of phenobarbital-responsive cytochrome P450 CYP2B genes. J Biochem Mol Toxicol 12: 39.[CrossRef][Medline]
Honkakoski P, Zelko I, Sueyoshi T, and Negishi M (1998b) The nuclear orphan receptor CAR-retinoid X receptor heterodimer activate the phenobarbital-responsive enhancer module of the cyp2b10 gene. Mol Cell Biol 18: 56525658.
Hosseinpour F, Moore R, Negishi M, and Sueyoshi T (2005) Serine 202 regulates the nuclear translocation of constitutive active/androstane receptor. Mol Pharmacol 69: 10951102.[CrossRef][Medline]
Joannard F, Rissel M, Gilot D, Anderson A, Orfila-Lefeuvre L, Guillouzo A, Atifi A, and Lagadic-Gossmann D (2006) Role for mitogen-activated protein kinases in phenobarbital-induced expression of cytochrome P450 2B in primary cultures of rat hepatocytes. Toxicol Lett 161: 6172.[CrossRef][Medline]
Kawamoto T, Sueyoshi T, Zelko I, Moore R, Washburn K, and Negishi M (1999) Phenobarbital-responsive nuclear translocation of the receptor CAR in induction of CYP2B gene. Mol Cell Biol 19: 63186322.
Kobayashi K, Sueyoshi T, Inoue K, Moore R, and Negishi M (2003) Cytoplasmic accumulation of the nuclear receptor CAR by a tetratricopeptide repeat protein in HepG2 cells. Mol Pharmacol 64: 10691075.
Kodama S and Negishi M (2006) Phenobarbital confers its divers effects by activating the orphan nuclear receptor CAR. Drug Metab Rev 38: 7587.[CrossRef][Medline]
Rencurel F, Foretz M, Kaufmann MR, Stroka D, Looser R, Leclerc I, Xavier GS, Rutter GA, Viollet B, and Meyer UA (2006) Stimulation of AMP-activated protein kinase is essential for the induction of drug metabolizing enzymes by phenobarbital in human and mouse liver. Mol Pharmacol 70: 19251934.
Rencurel F, Stenhouse A, Hawley SA, Friedberg T, Hardie DG, Sutherland C, and Wolf CR (2005) AMP-activated protein kinase mediates Phenobarbital induction of cyp2b gene expression in hepatocytes and a newly derived human hepatoma cell line. J Biol Chem 280: 43674373.
Seger R and Krebs EG (1995) The MAPK signaling cascade. FASEB J 9: 726735.[Abstract]
Shindo S, Numazawa S, and Yoshida T (2007) A physiological role of AMP-activated protein kinase in phenobarbital-mediated constitutive androstane receptor activation and CYP2B induction. Biochem J 401: 735741.[CrossRef][Medline]
Sidhu JS and Omiecinski CJ (1995) cAMP-associated inhibition of Phenobarbital-induced cytochrome P450 gene expression in primary rat hepatocyte cultures. J Biol Chem 270: 1276212773.
Sueyoshi T, Kawamoto T, Zelko I, Honkakoski P, and Negishi M (1999) The repressed nuclear receptor CAR responds to phenobarbital in activating the human cyp2b6 gene. J Biol Chem 274: 60436046.
Swales K, Kakizaki S, Yamamoto Y, Inoue K, Kobayashi K, and Negishi M (2005) Novel CAR-mediated mechanism for synergistic activation of two distinct elements within the human cytochrome P450 2b6 gene in HepG2 cells. J Biol Chem 280: 34583466.
Swales K and Negishi M (2004) CAR, driving into the future. Mol Endocrinol 18: 15891598.
Tzameli I, Pissios P, Schuetz EG, and Moore DD (2000) The xenobiotic compound 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene is an agonist ligand for the nuclear receptor CAR. Mol Cell Biol 20: 29512958.
Yamamoto Y, Kawamoto T, and Negishi M (2003) The role of the nuclear receptor CAR as a coordinate regulator of hepatic gene expression in defense against chemical toxicity. Arch Biochem and Biophys 409: 207211.[CrossRef][Medline]
Yamamoto Y, Moore R, Goldsworthy TL, Negishi M, and Maronpot RR (2004) The orphan nuclear receptor constitutive active/androstane receptor is essential for liver tumor promotion by phenobarbital in mice. Cancer Res 64: 71977200.
Yoshinari K, Kobayashi K, Moore R, Kawamoto T, and Negishi T (2003) Identification of the nuclear receptor CAR: HSP90 complex in mouse liver and recruitment of protein phosphatase 2A in response to phenobarbital. FEBS Lett 548: 1720.[CrossRef][Medline]
Zelko I, Sueyoshi T, Kawamoto T, Moore R, and Negishi M (2001) The peptide near the C terminus regulates receptor CAR nuclear translocation induced by xenochemicals in mouse liver. Mol Cell Biol 21: 28382846.
This article has been cited by other articles:
![]() |
M. Le Vee, V. Lecureur, A. Moreau, B. Stieger, and O. Fardel Differential Regulation of Drug Transporter Expression by Hepatocyte Growth Factor in Primary Human Hepatocytes Drug Metab. Dispos., November 1, 2009; 37(11): 2228 - 2235. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. D. Merrell, J. P. Jackson, L. M. Augustine, C. D. Fisher, A. L. Slitt, J. M. Maher, W. Huang, D. D. Moore, Y. Zhang, C. D. Klaassen, et al. The Nrf2 Activator Oltipraz Also Activates the Constitutive Androstane Receptor Drug Metab. Dispos., August 1, 2008; 36(8): 1716 - 1721. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Inoue and M. Negishi Nuclear Receptor CAR Requires Early Growth Response 1 to Activate the Human Cytochrome P450 2B6 Gene J. Biol. Chem., April 18, 2008; 283(16): 10425 - 10432. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Sueyoshi, R. Moore, J. Sugatani, Y. Matsumura, and M. Negishi PPP1R16A, The Membrane Subunit of Protein Phosphatase 1{beta}, Signals Nuclear Translocation of the Nuclear Receptor Constitutive Active/Androstane Receptor Mol. Pharmacol., April 1, 2008; 73(4): 1113 - 1121. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||